Skip to main content
OpenTrials
Completed

NCT Number: NCT00752219

Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

UMHAT Sveti Georgi 3rd Clinical of Surgery, Plovdiv, Bulgaria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • complicated intra-abdominal infections

Exclusion criteria

  • infections limited to hollow viscus
  • ischemic bowel disease without perforation
  • acute suppurative cholangitis
  • acute necrotizing pancreatitis
  • pts to undergo stated abdominal repair, open abdomen technique or marsupialization
  • Apache II >25

Treatment and study plan

ceftazidime/NXL104 + metronidazole

Drug

IV TID

Meropenem

Drug

IV TID

Other names: merrem

Primary outcomes

  1. Number of Participants With Clinical Response at the Test of Cure (TOC) Visit

    Time frame: Test of cure visit: 2 weeks post-therapy (Day 28)

    Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were microbiologically evaluable (ME) at baseline.

  2. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to 6 weeks after last dose of study treatment (up to a maximum of 8 weeks)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 weeks after last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state.

Secondary outcomes

  1. Number of Participants With Clinical Response at the End of Intravenous (IV) Therapy

    Time frame: End of IV therapy: From Day 5 to Day 14

    Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline.

  2. Number of Participants With Clinical Response at the Late Follow-up Visit

    Time frame: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)

    Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline.

  3. Number of Participants With Microbiological Response at the Test of Cure Visit

    Time frame: Test of cure visit: 2 weeks post-therapy (Day 28)

    Microbiological response was defined as eradication of pathogen identified (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication of pathogens (absence of material to culture in a participant who had responded clinically to treatment). This clinical response was measured in participants who were ME at baseline.

  4. Number of Participants With Microbiological Response at the End of IV Therapy

    Time frame: End of IV therapy: From Day 5 to Day 14

    Microbiological response was defined as eradication of pathogen identified (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication of pathogens (absence of material to culture in a participant who had responded clinically to treatment). This clinical response was measured in participants who were ME at baseline.

  5. Number of Participants With Microbiological Response at the Late Follow-up Visit

    Time frame: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)

    Favorable: eradication (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication (absence of material to culture in a patient who had responded clinically to treatment)

  6. Number of Participants With Clinical Response in Clinically Evaluable (CE) Participants at the Test of Cure Visit

    Time frame: Test of cure visit: 2 weeks post-therapy (Day 28)

    Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required.

  7. Number of Participants With Clinical Response in CE Participants at the End of IV Therapy

    Time frame: End of IV therapy: From Day 5 to Day 14

    Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required.

  8. Number of Participants With Clinical Response in CE Participants at the Late Follow-up Visit

    Time frame: Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)

    Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adults

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Sep 15, 2008
Registry last updated
Jul 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.